IRIS
GALLUZZO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.090
AS - Asia 3.390
EU - Europa 2.151
Continente sconosciuto - Info sul continente non disponibili 699
SA - Sud America 461
AF - Africa 56
OC - Oceania 7
Totale 21.854
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.880
SG - Singapore 1.555
IT - Italia 637
CN - Cina 489
RU - Federazione Russa 363
BR - Brasile 362
BD - Bangladesh 352
HK - Hong Kong 341
VN - Vietnam 246
IE - Irlanda 238
DE - Germania 210
GB - Regno Unito 137
FR - Francia 136
JP - Giappone 109
CA - Canada 106
FI - Finlandia 95
UA - Ucraina 75
IN - India 73
NL - Olanda 54
ID - Indonesia 50
SE - Svezia 46
KR - Corea 35
AR - Argentina 34
PL - Polonia 34
ES - Italia 29
AT - Austria 28
CO - Colombia 23
MX - Messico 23
JM - Giamaica 17
PK - Pakistan 17
TR - Turchia 17
ZA - Sudafrica 16
PH - Filippine 14
CH - Svizzera 13
EC - Ecuador 13
HN - Honduras 12
IQ - Iraq 12
CR - Costa Rica 10
MA - Marocco 10
MY - Malesia 9
PY - Paraguay 9
VE - Venezuela 9
CL - Cile 8
NP - Nepal 8
TT - Trinidad e Tobago 8
LT - Lituania 7
PT - Portogallo 7
UZ - Uzbekistan 7
AU - Australia 6
BE - Belgio 6
RO - Romania 6
SA - Arabia Saudita 6
TH - Thailandia 6
EE - Estonia 5
GR - Grecia 5
GT - Guatemala 5
IL - Israele 5
IR - Iran 5
KG - Kirghizistan 5
PA - Panama 5
PR - Porto Rico 5
SV - El Salvador 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
KE - Kenya 4
KZ - Kazakistan 4
NG - Nigeria 4
TN - Tunisia 4
TW - Taiwan 4
EG - Egitto 3
ET - Etiopia 3
EU - Europa 3
LB - Libano 3
MN - Mongolia 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BZ - Belize 2
DK - Danimarca 2
GE - Georgia 2
GP - Guadalupe 2
JO - Giordania 2
NI - Nicaragua 2
PE - Perù 2
SC - Seychelles 2
SN - Senegal 2
AD - Andorra 1
AW - Aruba 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
CG - Congo 1
CI - Costa d'Avorio 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
Totale 21.148
Salva come PNG Salva come JPEG
Città #
Wilmington 3.188
Houston 2.950
Woodbridge 1.607
Ashburn 910
Singapore 760
Fairfield 687
San Jose 589
Council Bluffs 379
Hong Kong 335
Seattle 334
Chandler 302
Cambridge 255
Dublin 219
Ann Arbor 191
Dallas 184
Beijing 164
Santa Clara 160
The Dalles 159
Medford 152
Rome 116
New York 113
Los Angeles 106
Tokyo 96
Dearborn 93
Ho Chi Minh City 81
Lawrence 72
Buffalo 68
Munich 68
North Bergen 68
Hanoi 66
Lauterbourg 64
Milan 59
Moscow 58
San Diego 56
Jacksonville 47
Helsinki 39
São Paulo 38
Redondo Beach 36
Lappeenranta 34
Nuremberg 34
Atlanta 32
Toronto 32
Jakarta 31
London 30
Chennai 28
Chicago 28
Denver 28
Phoenix 28
Montreal 26
Orem 22
Del Norte 21
Seoul 21
Zhengzhou 21
Brooklyn 20
Naples 20
Salt Lake City 20
Menlo Park 18
Boardman 17
Perugia 17
Redwood City 16
Warsaw 16
Boston 15
Charlotte 15
Colorado Springs 15
Frankfurt am Main 15
Shanghai 14
Vienna 14
Esslingen am Neckar 13
Hyderabad 13
Kingston 13
Kraków 13
Manchester 13
Bologna 12
Johannesburg 12
Columbus 11
San Francisco 11
Falls Church 10
Genoa 10
Guangzhou 10
Amsterdam 9
Philadelphia 9
Pune 9
Saint Petersburg 9
Turku 9
Ankara 8
Brasília 8
Da Nang 8
Haiphong 8
Mexico City 8
Palermo 8
Stockholm 8
Turin 8
Asunción 7
Catania 7
Dhaka 7
Engelhard 7
Miami 7
Ottawa 7
Poplar 7
Porto Alegre 7
Totale 15.823
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 553
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 471
Brodalumab for the treatment of psoriasis 466
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 442
Tildrakizumab for treating psoriasis 430
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 427
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 425
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 411
Tofacitinib for the treatment of psoriasis 410
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 408
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 403
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies 395
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 386
A safety evaluation of guselkumab for the treatment of psoriasis 380
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 379
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 365
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. 361
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 358
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 357
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 342
Photo-recall cutaneous reaction to gemcitabine 333
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 330
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 311
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 307
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 300
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 296
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 286
Pharmacotherapeutic management of psoriasis in adolescents and children 284
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 278
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 273
Skin immunity and its dysregulation in psoriasis 269
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 265
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy 258
Successful treatment of psoriatic crumbly nails with ustekinumab 257
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 253
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 251
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 231
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 217
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 213
letter in response to the case report: “recalcitrant generalized granuloma annulare treated successfully with dupilumab” 211
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 179
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 156
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 155
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience 152
Italian guidelines in diagnosis and treatment of alopecia areata 148
Effectiveness of brodalumab for the treatment of moderate-to-severe psoriasis: a retrospective, real-world multicenter study with a focus on obese and multi-failure patients—IL PSO (Italian Landscape Psoriasis) 148
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 143
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) 142
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 140
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 135
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 135
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients 132
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 128
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: The EARLY study 126
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View 125
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series 122
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 122
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 121
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 121
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 120
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 116
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks 114
BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis) 111
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 111
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 110
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 110
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis 108
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 105
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 103
Quality of life and psychological impact in patients with atopic dermatitis 103
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 102
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 100
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 99
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 99
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab 98
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 98
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study–IL PSO (Italian Landscape Psoriasis) 96
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 96
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis 95
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol? 95
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 95
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study 94
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 94
Linear psoriasis following the typical distribution of the sciatic nerve 93
successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series 92
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study 92
Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseases 91
Eczematous liraglutide eruption managed by dupilumab: A case report 89
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 89
Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: A multicentre real-life experience in Lazio region, Italy 88
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 88
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 87
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry 87
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 86
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice 82
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 81
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study 81
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study 80
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS) 80
A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis? 80
Totale 20.160
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.879
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.879
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022665 0 0 0 14 31 35 140 34 60 52 73 226
2022/2023807 101 81 69 61 55 207 68 32 57 22 30 24
2023/2024565 33 6 15 16 45 80 93 51 3 40 120 63
2024/20252.543 101 412 246 266 49 279 108 119 238 198 315 212
2025/20264.864 293 158 578 254 359 152 627 526 565 519 370 463
2026/20272.078 254 277 889 658 0 0 0 0 0 0 0 0
Totale 21.854